SOUTH SAN FRANCISCO, Calif., May 27, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced publication of preclinical data on its second-generation, dual-action vascular disrupting agent (VDA) OXi4503 that demonstrate potent activity against acute myeloid leukemia (AML). The data were published in Blood in an article entitled, "Leukemia regression by vascular disruption and anti-angiogenic therapy" by Gerard Madlambayan, Christopher Cogle and colleagues from the Department of Medicine and Program in Stem Cell Biology at the University of Florida in Gainesville, Florida. The data are available online, ahead of print on the Blood website: http://bloodjournal.hematologylibrary.org/cgi/reprint/blood-2009-06-230474v1.
